Reciprocal relationships between abnormal metabolic parameters and endothelial dysfunction

Current Opinion in Lipidology

Volumn 18, Issue 1, 2007, Pages 58-65

  Han, Seung Hwan ^a   Quon, Michael J ^b   Koh, Kwang Kon ^a  

^a Gachon University College of Medicine   (South Korea)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Endothelial dysfunction; Insulin resistance; Metabolic syndrome

Indexed keywords

ACETYLCYSTEINE; ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; CARDIOVASCULAR AGENT; DIMETHYLARGININASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; FENOFIBRATE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CORRELATION ANALYSIS; DIET; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EXERCISE; GLYCATION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; METABOLIC ACTIVATION; METABOLIC DISORDER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VASCULAR DISEASE;

DIET; DIETARY FATS; ENDOTHELIUM, VASCULAR; FATTY ACIDS, NONESTERIFIED; HUMANS; INSULIN RESISTANCE; METABOLIC DISEASES;

EID: 33846154584     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328012b627     Document Type: Review

References (56)

1. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000; 47:648-657.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
3. Kim JA, Koh KK, Quon MJ. The union of vascular and metabolic actions of insulin in sickness and in health. Arterioscler Thromb Vasc Biol 2005; 25:889-891. This editorial reviews the mechanisms coupling vascular and metabolic physiology, the role of inflammation in insulin resistance and endothelial dysfunction, and the role of insulin resistance to couple vascular and metabolic pathophysiology.
4. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113:1888-1904. Comprehensive review of cellular, physiological, clinical, and epidemiological studies which strongly support a reciprocal relationship between endothelial dysfunction and insulin resistance that help link cardiovascular and metabolic diseases.
5. Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep 2003; 3:279-288.
6. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
7. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341: 410-418.
8. Nystrom FH, Quon MJ. Insulin signalling: metabolic pathways and mechanisms for specificity. Cell Signal 1999; 11:563-574.
9. Potenza MA, Marasciulo FL, Mitolo Chieppa D, et al. Insulin resistance in spontaneously hypertensive rats (SHR) is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 2005; 289:H813-H822. This study demonstrates that insulin resistance in SHR rats is accompanied by endothelial dysfunction in mesenteric vessels with impaired PI 3-kinase-dependent NO production and enhanced MAPK-dependent ET-1 secretion. These results may reflect pathophysiology in other vascular beds that directly contribute to elevated peripheral vascular resistance and hypertension.
10. Potenza MA, Marasciulo FL, Tarquinio M, et al. Treatment of spontaneously hypertensive rats (SHR) with rosiglitazone and/or enalapril simultaneously improves hypertension and insulin resistance by restoring balance between vasodilator and vasoconstrictor actions of insulin. Diabetes (in press).
11. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man: a novel mechanism for insulin resistance. J Clin Invest 1990; 85:1844-1852.
12. Algenstaedt P, Schaefer C, Biermann T, et al. Microvascular alterations in diabetic mice correlate with level of hyperglycaemia. Diabetes 2003; 52:542-549.
13. Schiekofer S, Andrassy M, Chen J, et al. Acute hyperglycemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 2003; 52:621-633.
14. Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 1999; 48:1856-1862.
15. Rodriguez CJ, Miyake Y, Grahame-Clarke C, et al. Relation of plasma glucose and endothelial function in a population-based multiethnic sample of subjects without diabetes mellitus. Am J Cardiol 2005; 96:1273-1277. This study clearly demonstrates significant relationships between endothelial flow-mediated dilation (FMD) and fasting plasma glucose among a multiethnic population-based cohort of 579 nondiabetic subjects without previous myocardial infarction or stroke enrolled in the Northern Manhattan Study.
16. Yasuda S, Miyazaki S, Kanda M, et al. Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. Eur Heart J 2006; 27:1159-1165.
17. Title LM, Cummings PM, Giddens K, Nassar BA. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. J Am Coll Cardiol 2000; 36:2185-2191.
18. Tushuizen ME, Nieuwland R, Scheffer PG, et al. Two consecutive high-fat meals affect endothelial-dependent vasodilation, oxidative stress and cellular microparticles in healthy men. J Thromb Haemost 2006; 4:1003-1010.
19. Sorensen VR, Mathiesen ER, Clausen P, et al. Impaired vascular function during short-term poor glycaemic control in Type 1 diabetic patients. Diabet Med 2005; 22:871-876.
20. Nieuwdorp M, van Haeften TW, Gouverneur MC, et al. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes 2006; 55:480-486. This study investigates the role of the endothelial glycocalyx to mediate effects of hyperglycemia on endothelial dysfunction. Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and activation of coagulation pathways in healthy male subjects.
21. Susic D, Varagic J, Ahn J, Frohlich ED. Crosslink breakers: a new approach to cardiovascular therapy. Curr Opin Cardiol 2004; 19:336-340.
22. Zieman SJ, Kass DA. Advanced glycation endproduct crosslinking in the cardiovascular system: potential therapeutic target for cardiovascular disease. Drugs 2004; 64:459-470.
23. Miele C, Riboulet A, Maitan MA, et al. Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase C alpha-mediated mechanism. J Biol Chem 2003; 278:47376-47387.
24. Wautier MP, Chappey O, Corda S, et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol 2001; 280:E685-E694.
25. Hlfmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 1999; 97:889-901.
26. Park L, Raman KG, Lee KJ, et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 1998; 4:1025-1031.
27. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54:1615-1625. Excellent and comprehensive review of a unifying mechanism underlying the pathobiology of diabetic complications. Authors focus on novel therapeutic approaches for the prevention and treatment of diabetic complications.
28. Du XL, Edelstein D, Rossetti L, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 2000; 97:12222-12226.
29. Tripathy D, Mohanty P, Dhindsa S, et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003; 52:2882-2887.
30. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 2002; 45:623-634.
31. Inoguchi T, Li P, Umeda F, et al. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000; 49:1939-1945.
32. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005; 307:384-387. This excellent review examines emerging evidence to support the hypothesis that both insulin resistance and endothelial dysfunction in Type 2 diabetes are related to mitochondrial dysfunction.
33. Kim F, Tysseling KA, Rice J, et al. Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol 2005; 25:989-994. This excellent study demonstrates that elevated levels of common FFAs found in human serum activate IKKβ in endothelial cells leading to reduced NO production which may serve to link pathways involved in inflammation, endothelial dysfunction, and insulin resistance.
34. Du X, Edelstein D, Obici S, et al. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J Clin Invest 2006; 116:1071-1080. This study demonstrates that increased oxidation of FFAs in aortic endothelial cells without added insulin causes increased production of superoxide by the mitochondrial electron transport chain and inactivates 2 important antiatherogenic enzymes, prostacyclin synthase and eNOS.
35. de Man FH, Weverling-Rijnsburger AW, van der Laarse A, et al. Not acute but chronic hypertriglyceridemia is associated with impaired endothelium-dependent vasodilation: reversal after lipid-lowering therapy by atorvasatatin. Atherioscler Thromb Vasc Biol 2000; 20:744-750.
36. Han SH, Quon MJ, Kim J, Koh KK. Adiponectin and cardiovascular disease: response to therapeutic interventions. J Am Coll Cardiol (in press).
37. Salmenniemi U, Ruotsalainen E, Pihlajamaki J, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 2004; 110:3842-3848.
38. Chen H, Montagnani M, Funahashi T, et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278:45021-45026.
39. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, adipocyte-derived protein, inhibits endothelial NFkB signaling through cAMP-dependent pathway. Circulation 2000; 102:1296-1301.
40. Tan KC, Xu A, Chow WS, Lam MC, et al. Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 2004; 89:765-769.
41. Hamdy O, Ledbury S, Mullooly C, et al. Life-style modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care 2003; 26:2110-2125.
42. Han SH, Quon MJ, Koh KK. Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators. Hypertension 2005; 46:1086-1092. Excellent and comprehensive review of mechanisms underlying vascular and metabolic effects of fibrates that may synergize to prevent or regress atherosclerosis and coronary heart disease.
43. Koh KK, Han SH, Quon MJ, et al. Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005; 28:1419-1424. This clinical study demonstrates that fenofibrate significantly improves endothelial function and raises adiponectin levels in patients with primary hypertriglyceridemia.
44. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-1861. The large scale clinical study evaluates the efficacy of fenofibrate in subjects with 9795 participants aged 50-75 years, with type 2 diabetes mellitus. Some conclusions are limited by inadequate study design.
45. Pistrosch F, Passauer J, Fischer S, et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27:484-490.
46. Campia U, Matuskey LA, Panza JA. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 2006; 113:867-875. This clinical study demonstrates that pioglitazone treatment enhances insulin sensitivity, decreases C-reactive protein, and improves endothelial vasodilator function in nondiabetic patients with cardiovascular risk factors.
47. Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289. The Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROACTIVE) is a secondary prevention trial that compares effects of pioglitazone and placebo in subjects with type 2 diabetes.
48. Koh KK, Quon MJ, Han SH, et al. Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2006; 108:96-100. This clinical study demonstrates that candesartan, an angiotensin II type 1 receptor blocker, has beneficial anti-inflammatory and metabolic effects in hypertensive patients.
49. Koh KK, Quon MJ, Han SH, et al. Vascular and metabolic effects of candesartan: insights from therapeutic interventions. J Hypertens Suppl 2006; 24:S31-S38. Comprehensive review of beneficial vascular and metabolic effects of candesartan.
50. Koh KK, Quon MJ, Han SH, et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005; 45:1088-1093. This clinical study demonstrates that combined therapy with ramipril and simvastatin has additive beneficial vascular and metabolic effects in patients type 2 diabetes when compared with respective monotherapies.
51. Yusuf S, Ostergren JB, Gerstein HC, et al. Candesartan in heart failure assessment of reduction in mortality and morbidity program investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112:48-53. This large scale clinical study demonstrates that the angiotensin receptor blocker candesartan prevents new onset diabetes in heart failure patients suggesting a role for the renin-angiotensin axis in glucose homeostasis.
52. The DREAM Trial investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med (in press).
53. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004; 110:3687-3692.
54. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005; 45:1649-1653.
55. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. Diabetes Care 2006; 29:195-201. This clinical study demonstrates that combined therapy with fenofibrate and candesartan has additive beneficial vascular and metabolic effects in hypertriglyceridemic, hypertensive patients when compared with respective monotherapies.
56. Koh KK, Han SH, Quon MJ. Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions. J Am Coll Cardiol 2005; 46:1978-1985. Excellent and comprehensive review of inflammatory markers and the metabolic syndrome with insights from therapeutic interventions.